Biodesix Inc. (BDSX) intrinsic value & 10-year financials
Biodesix Inc. (BDSX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 23.8% a year to $88.5M, with an average return on invested capital of -248.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $23.66
- Market cap
- $178.7M
- Revenue (FY2025)
- $88.5M
- Revenue growth (8-yr CAGR)
- 23.8%
- ROIC (10-yr avg)
- -248.1%
- Free cash flow (FY2025)
- -$23.5M
BDSX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $88.5M | -$35.3M | -$4.67 | -$23.5M | -31.5% | -49.7% |
| FY2024 | $71.3M | -$42.9M | -$0.33 | -$51.9M | -48.4% | -66.9% |
| FY2023 | $49.1M | -$52.1M | -$0.64 | -$45.8M | -84.2% | -146.3% |
| FY2022 | $38.2M | -$65.4M | -$0.78 | -$48.3M | -132.4% | -1006.0% |
| FY2021 | $54.5M | -$43.2M | -$0.79 | -$30.5M | -75.1% | -509.6% |
| FY2020 | $45.6M | -$31.4M | — | -$23.3M | -50.3% | 26.1% |
| FY2019 | $24.6M | -$30.7M | — | -$23.0M | -108.9% | 15.8% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BIODESIX INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BIODESIX INC has historically struggled to out-earn its cost of capital, averaging just -33.7% ROIC.
BIODESIX INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BIODESIX INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-155.12 per share.